Cocrystal Pharma (COCP) Profit After Tax (2010 - 2026)

Cocrystal Pharma has reported Profit After Tax for 17 years, with the latest figure at -$2.3 million in Q1 2026.

• Quarterly Profit After Tax changed 0.09% year-over-year to -$2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.8 million (up 44.49% YoY) and the FY2025 annual result came in at -$8.8 million, up 49.73% from the prior year.
• Profit After Tax improved to -$2.3 million in Q1 2026 per COCP's latest filing, from -$2.4 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$2.0 million in Q3 2025 and troughed at -$24.4 million in Q2 2022.
• A 5-year average of -$5.0 million and a median of -$4.2 million in 2023 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2022 and 2023: Profit After Tax tumbled 539.31% in 2022, then surged 82.95% in 2023.
• Over 5 years, Profit After Tax stood at -$4.5 million in 2022, then grew by 0.82% to -$4.5 million in 2023, then rose by 26.84% to -$3.3 million in 2024, then grew by 26.67% to -$2.4 million in 2025, then advanced by 4.01% to -$2.3 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$2.3 million, -$2.4 million, and -$2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.